An experimental HIV therapy booster from Gilead Sciences Inc. — a key part of Gilead’s experimental four-in-one, once-a-day Quad pill — met the goal of a Phase III trial, the company said Monday.
The booster, named cobicistat, showed in the 96-week study that it was at least on par with ritonvair, or Norvir, from Abbott Laboratories (NYSE: ABT), Gilead (NASDAQ: GILD) said.
No comments:
Post a Comment